GE Healthcare and BAC B.V. Collaborate to Launch New Bioprocess Affinity Resin
Published: Mar 19, 2012
CHALFONT ST GILES, England & NAARDEN, The Netherlands--(BUSINESS WIRE)--GE Healthcare, the healthcare business of GE (NYSE: GE) and BAC BV, the leading provider of antibody-based affinity purification technology, announced today that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new and innovative affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare’s new resin, LambdaFabSelect, is a designed tool for the GMP-regulated purification of antibodies and antibody fragments that contain a lambda light chain. Antibody fragments are receiving increased attention as potential future biopharmaceuticals because, compared with monoclonal antibodies, they have a number of advantages such as improved tissue penetration and the ability to bind to targets inaccessible to conventional antigen-binding sites.